Stevanato Group (STVN) Q1 2026 earnings review
Solid Biologics Growth Masked by Engineering Slump and BDS Margin Compression
Stevanato delivered 7% YoY revenue growth (10% at constant currency), driven entirely by its core Biopharmaceutical and Diagnostic Solutions (BDS) segment (+13%). The company is successfully capitalizing on the GLP-1 boom, with these blockbuster drugs now representing 21-22% of total sales. However, beneath the surface, the numbers show significant stress: BDS gross margins collapsed by 300 bps due to new facility depreciation and tariffs, and the Engineering segment saw revenue plummet 31% amid a slow order environment. Full-year guidance was maintained, implying a steep acceleration in earnings for the remaining quarters.
🐂 Bull Case
Biologics end-market revenue grew 15%, and GLP-1 treatments now make up over 21% of total revenue, proving STVN is deeply entrenched in the industry's fastest-growing segment.
Premium HVS products grew 17% YoY and now represent 47% of revenue, continuing the structural shift away from low-margin standard vials.
🐻 Bear Case
Despite the richer product mix, BDS gross margins fell 300 bps to 28.3%. High depreciation from the new Fishers and Latina facilities is heavily diluting profitability during the scale-up phase.
Engineering revenue collapsed 31% YoY. Management's note on the 'slow pace of orders' suggests pharma customers are aggressively delaying capital equipment purchases.
⚖️ Verdict: ⚪
Neutral. The long-term biologics demand story is intact, but the margin profile is taking a heavy hit from capacity build-outs, and the Engineering segment needs to prove its decline is just delayed orders, not lost market share.
Key Themes
BDS Gross Margin Collapse Contradicts Mix Narrative
A major red flag: despite High-Value Solutions growing 17%, the core BDS segment suffered a severe 300 bps gross margin contraction, falling from 31.3% to 28.3%. This directly contradicts the narrative that a richer product mix automatically yields better margins. Management cited higher depreciation from new lines in Fishers and Latina, meaning fixed costs are heavily outweighing the volume and mix benefits during this phase of the scale-up.
Engineering Segment Demand Shock
The Engineering segment's top line is reversing aggressively, with revenue collapsing 31% YoY to €24.6M. This is a severe deterioration compared to the mid-single-digit decline forecasted in prior quarters. Management explicitly cited a 'cautious' environment due to the 'slow pace of orders' and lower converting/assembly volume, suggesting pharmaceutical customers are heavily delaying their capital expenditures.
Macro Headwinds: Tariffs and FX
Macroeconomic factors are biting into profitability. Management explicitly called out foreign currency translation and the unfavorable impact of tariffs as direct drivers of the gross margin decline in Q1. While Stevanato attempted to pass tariff costs to customers in FY25, the Q1 results indicate that current geopolitical trade frictions are outstripping their immediate pricing power.
Biologics and GLP-1 Dominance
Stevanato is successfully riding the largest wave in pharmaceuticals. Revenue from biologics increased 15% YoY, driven heavily by GLP-1 treatments which now account for an astounding 21-22% of total company revenue. The specific adoption of their Nexa high-performance syringes and EZ-fill products for these complex, large-molecule blockbuster drugs proves their technological moat is secure.
High-Value Solutions Mix
The structural shift toward premium products remains stable and accretive to the top line. High-Value Solutions (HVS) grew 17% YoY to €128.6M, now representing 47% of total revenue. Even with the depreciation drag, mixing up the portfolio to these higher-priced containment solutions is the primary driver keeping the company's consolidated revenue growth positive.
Engineering Margin Optimization
In a surprising break from the revenue collapse, the Engineering segment's gross profit margin accelerated 460 bps YoY to 15.3%. The aggressive business optimization plan—right-sizing operations in Denmark and shifting labor costs—is yielding tangible results. Management is proving they can defend bottom-line profitability even when top-line demand evaporates.
Other KPIs
Decelerating. FCF was positive but dropped substantially from €29.7M in 25Q1. Cash flow from operations declined from €99.8M to €75.5M, while CapEx remained heavily elevated at €67.6M as the company continues building out the Indiana and Italy plants. The balance sheet remains stable with €111.7M in cash.
Accelerating. Despite the massive gross margin compression in the BDS segment, consolidated Adjusted EBITDA margin improved 150 basis points YoY (from 22.4%). This was largely driven by tighter operating cost controls and the margin improvements within the Engineering segment's restructured operations.
Guidance
Stable. Management maintained its full-year outlook. The midpoint of €1.275B implies a roughly 7.5% YoY growth rate over FY25. Given that 26Q1 delivered exactly 7% growth, this suggests the company expects the growth rate to remain steady or slightly accelerate through the remainder of the year, relying heavily on continued GLP-1 momentum.
Stable. The maintained EPS guidance points to an expected acceleration in earnings in the back half of the year. With 26Q1 Adjusted EPS at €0.11, Stevanato must average €0.17 per quarter for the rest of FY26 to hit the midpoint. While Q1 is historically the seasonally weakest quarter, hitting this target requires the new Fishers and Latina facilities to rapidly overcome their current depreciation drag.
Key Questions
Engineering Demand Pipeline
The 31% revenue drop in Engineering is much steeper than the mid-single to low-double digit decline forecasted during the Q4 call. Is this purely an order timing issue, or are customers fundamentally re-evaluating their capital expenditure plans for the year?
BDS Margin Inflection Point
BDS gross margins fell 300 bps to 28.3%, largely due to new facility depreciation. At what capacity utilization level do you expect the Fishers and Latina facilities to flip from being a gross margin drag to becoming margin accretive?
Non-Recurring Accretive Projects
You mentioned that a pilot NFHU fill-and-finish project did not recur this quarter, which negatively impacted margins. Was this a one-off, or is there a robust pipeline for similar accretive services to support margins in late FY26?
GLP-1 Market Evolution
GLP-1 treatments now account for 21-22% of revenue. As the market transitions more towards oral formulations or biosimilars over the next 2-3 years, how is Stevanato positioning its High-Value Solutions portfolio to defend and grow these volumes?